
  
    
      
        
        A_DT malaria_NN vaccine_NN called_VBN ME-TRAP_NNP ,_, which_WDT targets_VBZ the_DT pre-erythrocytic_JJ stage_NN of_IN the_DT
        disease_NN ,_, was_VBD not_RB effective_JJ at_IN reducing_VBG natural_JJ infection_NN rates_NNS in_IN semi-immune_JJ African_JJ
        adults_NNS ,_, according_VBG to_TO the_DT report_NN of_IN a_DT randomized_JJ controlled_VBN trial_NN published_VBD this_DT month_NN in_IN 
        PLoS_NNP Medicine_NNP ._. “ This_DT first_JJ field_NN efficacy_NN trial_NN was_VBD an_DT important_JJ
        milestone_NN in_IN the_DT progression_NN of_IN new_JJ recombinant_JJ vectored_JJ vaccines_NNS to_TO deployable_JJ products_NNS ,_,”
        says_VBZ Adrian_NNP Hill_NNP (_( University_NNP of_IN Oxford_NNP ,_, United_NNP Kingdom_NNP )_) ,_, the_DT lead_JJ investigator_NN of_IN the_DT
        study_NN ._. “ The_DT safety_NN profile_NN was_VBD excellent_JJ and_CC the_DT efficacy_NN data_NN provide_VBP a_DT first_JJ indication_NN
        of_IN the_DT levels_NNS of_IN cellular_JJ immunogenicity_NN that_WDT will_MD be_VB required_VBN for_IN preventing_VBG infection_NN ,_,”
        he_PRP says_VBZ ._.
        Hill_NNP and_CC his_PRP$ co-workers_NNS used_VBD a_DT heterologous_JJ prime–boost_NN vaccination_NN technique_NN ._. They_PRP gave_VBD
        the_DT volunteers_NNS two_CD vaccines—a_NN DNA_NNP priming_VBG vaccine_NN followed_VBN by_IN a_DT modified_VBN vaccinia_NN virus_NN
        Ankara_NNP (_( MVA_NNP )_) that_WDT acted_VBD as_IN a_DT booster_NN ._. The_DT DNA_NNP and_CC MVA_NNP vaccines_NNS both_DT had_VBD the_DT same_JJ insert_NN
        coding_VBG for_IN thrombospondin-related_JJ adhesion_NN protein_NN (_( TRAP_NNP ;_: a_DT pre-erythrocytic_JJ antigen_NN )_) and_CC a_DT
        string_NN of_IN T_NN cell_NN epitopes_NNS (_( called_VBN ME_NNP for_IN “ multiple_JJ epitopes_NNS” )_) ._.
        Hill_NNP 's_POS team_NN had_VBD previously_RB shown_VBN that_IN ME-TRAP_NNP vaccines_NNS given_VBN in_IN prime–boost_NN sequence_NN
        could_MD induce_VB large_JJ T_NN cell_NN responses_NNS in_IN healthy_JJ volunteers_NNS from_IN the_DT UK_NNP and_CC could_MD delay_VB
        parasitemia_NN in_IN a_DT sporozoite_NN challenge_NN test_NN (_( Nat_NNP Med_NNP 9_CD :_: 729_CD –_NN 735_CD )_) ._. The_DT next_JJ step_NN was_VBD to_TO do_VB a_DT
        randomized_JJ controlled_VBN trial_NN in_IN Gambia_NNP to_TO determine_VB whether_IN this_DT vaccination_NN strategy_NN could_MD
        provide_VB protection_NN against_IN natural_JJ 
        Plasmodium_NNP falciparum_NN infection_NN ._.
        The_DT researchers_NNS recruited_VBD volunteers_NNS from_IN 13_CD Gambian_NNP villages_NNS that_WDT were_VBD close_RB to_TO the_DT
        alluvial_JJ flood_NN plain_JJ and_CC so_RB were_VBD at_IN high_JJ risk_NN of_IN developing_VBG malaria_NN ._. They_PRP randomly_RB assigned_VBN
        the_DT 372_CD volunteers_NNS to_TO receive_VB either_CC two_CD doses_NNS of_IN the_DT DNA_NNP ME-TRAP_NNP vaccine_NN followed_VBN by_IN a_DT
        single_JJ dose_NN of_IN MVA_NNP ME-TRAP_NNP ,_, or_CC three_CD doses_NNS of_IN rabies_NNS vaccine_NN ._. This_DT three-dose_JJ schedule_NN is_VBZ
        similar_JJ to_TO the_DT one_CD used_VBN by_IN the_DT World_NNP Health_NNP Organization_NNP /_NN United_NNP Nations_NNPS Children_NNP 's_POS Fund_NNP
        Expanded_NNP Program_NNP on_IN Immunization_NNP ._. Two_CD weeks_NNS before_IN the_DT third_JJ dose_NN was_VBD given_VBN ,_, all_PDT the_DT
        volunteers_NNS received_VBD antimalarial_NN drugs_NNS to_TO clear_VB blood-stage_JJ 
        P_NN ._. falciparum_NN infections_NNS ._.
        The_DT time_NN to_TO first_JJ infection_NN ,_, the_DT primary_JJ end_NN point_NN of_IN the_DT study_NN ,_, was_VBD similar_JJ in_IN the_DT two_CD
        groups_NNS ,_, with_IN an_DT estimated_VBN vaccine_NN efficacy_NN of_IN only_RB 10_CD %_NN ._. However_RB ,_, the_DT effector_NN T_NN cell_NN
        response_NN to_TO the_DT TRAP_NNP antigen_NN T_NN 9_CD /_NN 96_CD ,_, measured_VBD one_CD week_NN after_IN the_DT third_JJ vaccination_NN ,_, was_VBD 80_CD
        times_NNS higher_JJR in_IN the_DT DNA_NNP /_NN MVA_NNP vaccine_NN group_NN than_IN in_IN the_DT rabies_NNS vaccine_NN group_NN ._.
        “ It_PRP is_VBZ absolutely_RB crucial_JJ that_IN results_NNS like_IN these_DT are_VBP published_VBN ,_, since_IN the_DT failures_NNS ,_, as_RB
        well_RB as_IN the_DT successes_NNS ,_, need_VBP to_TO be_VB documented_VBN if_IN we_PRP are_VBP to_TO move_VB towards_IN rational_JJ strategies_NNS
        for_IN optimizing_VBG malaria_NN vaccines_NNS ,_,” says_VBZ Tom_NNP Smith_NNP from_IN the_DT Swiss_NNP Tropical_NNP Institute_NNP ,_, who_WP was_VBD
        not_RB involved_VBN in_IN the_DT study_NN ._. “ At_IN the_DT same_JJ time_NN ,_, it_PRP makes_VBZ sense_NN to_TO move_VB on_IN quickly_RB without_IN
        shedding_VBG too_RB many_JJ tears_NNS ,_, in_IN a_DT field_NN that_WDT is_VBZ moving_VBG much_JJ faster_RBR than_IN it_PRP was_VBD before_IN the_DT
        recent_JJ injections_NNS of_IN money_NN from_IN the_DT Gates_NNP Foundation_NNP ,_, but_CC where_WRB it_PRP is_VBZ still_RB impossible_JJ to_TO
        second-guess_VB the_DT results_NNS of_IN field_NN trials_NNS ._. This_DT is_VBZ partly_RB because_IN we_PRP do_VBP not_RB have_VB any_DT good_JJ
        proxy_NN measures_NNS of_IN effective_JJ immunity_NN in_IN 
        P_NN ._. falciparum_NN ,_, and_CC partly_RB because_IN this_DT is_VBZ a_DT fertile_JJ area_NN for_IN
        trying_VBG out_IN new_JJ techniques_NNS ,_, such_JJ as_IN DNA_NNP vaccines_NNS ,_, where_WRB there_EX is_VBZ still_RB a_DT lot_NN to_TO learn_VB ._.”
        Hill_NNP is_VBZ planning_VBG to_TO do_VB further_RB trials_NNS that_WDT address_VBP the_DT important_JJ question_NN of_IN whether_IN
        this_DT type_NN of_IN vaccine_NN can_MD prevent_VB the_DT symptoms_NNS of_IN malaria_NN ._. “ The_DT next_JJ step_NN ,_,” says_VBZ Hill_NNP ,_, “ is_VBZ
        to_TO assess_VB newer_JJR vaccine_NN regimes_NNS that_WDT employ_VBP two_CD viral_JJ vectors_NNS rather_RB than_IN DNA_NNP and_CC to_TO study_VB
        prevention_NN of_IN malaria_NN rather_RB than_IN infection_NN ._.”
      
    
  
